This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's (Adafi)

This study has been completed.
Information provided by (Responsible Party):
Foundation for Liver Research Identifier:
First received: August 15, 2008
Last updated: April 16, 2012
Last verified: April 2012
To assess whether a combination of ciprofloxacin and adalimumab is more effective than adalimumab alone for the treatment of perianal fistulas in Crohn's disease

Condition Intervention Phase
Crohn's Disease With Perianal Fistulas Drug: adalimumab Drug: ciprofloxacin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Adalimumab for the Treatment of Perianal Fistulas in Crohn's Disease More Effective Alone or Combined to Ciprofloxacin

Resource links provided by NLM:

Further study details as provided by Foundation for Liver Research:

Primary Outcome Measures:
  • Reduction of 50% or more from baseline to week 12 in the number of draining perianal fistulas. [ Time Frame: 12 week ]

Secondary Outcome Measures:
  • Proportion of patients in remission [ Time Frame: 12 week ]

Enrollment: 76
Study Start Date: September 2008
Study Completion Date: December 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: adalimumab
24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
Other Name: Humira
Placebo Comparator: 2
Drug: ciprofloxacin
12 weeks; daily 2 x 500mg
Other Name: Cipro

Detailed Description:
Dutch multicenter, randomized, double-blind study with two arms. 146 patients will be included.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • proven Crohn's disease
  • Single or multiple draining perianal fistulas

Exclusion Criteria:

  • Abscesses
  • Infliximab, cyclosporine, tacrolimus and antibiotics for Crohn's disease within past 3 months
  • active viral infection
  • significate cardiovascular dysfunction
  • Pregnancy, Lactation
  • Surgical bowel resection to be expected within 6 months
  • Positive stool culture for enteric pathogens
  • Total parental nutrition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00736983

Amsterdam, Netherlands
Amsterdam, Netherlands
Haga ziekenhuis
Den Haag, Netherlands
Deventer ziekenhuis
Deventer, Netherlands
Albert Schweitzer ziekenhuis
Dordrecht, Netherlands
Medisch Spectrum Twente
Enschede, Netherlands
UMC Gronigen
Groningen, Netherlands
Leiden, Netherlands
AZ Maastricht
Maastricht, Netherlands
St Antonius ziekenhuis
Nieuwegein, Netherlands
UMC Radboud
Nijmegen, Netherlands
Erasmus MC
Rotterdam, Netherlands
UMC Utrecht
Utrecht, Netherlands
Sponsors and Collaborators
Foundation for Liver Research
Principal Investigator: C.J. van der Woude, MD PhD Erasmus MC
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Foundation for Liver Research Identifier: NCT00736983     History of Changes
Other Study ID Numbers: IBD 08-01
EudraCT#: 2007-005832-10
Study First Received: August 15, 2008
Last Updated: April 16, 2012

Keywords provided by Foundation for Liver Research:
Perianal fistulas
Crohn's disease

Additional relevant MeSH terms:
Crohn Disease
Rectal Fistula
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Pathological Conditions, Anatomical
Intestinal Fistula
Digestive System Fistula
Rectal Diseases
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on September 21, 2017